financetom
Business
financetom
/
Business
/
Amerigo Resources Swings To Q2 Profit; Declared First Performance Dividend
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Amerigo Resources Swings To Q2 Profit; Declared First Performance Dividend
Jul 31, 2024 5:37 AM

08:16 AM EDT, 07/31/2024 (MT Newswires) -- Amerigo Resources Ltd. ( ARREF ) on Wednesday swung to a profit for the second quarter on a "significant strengthening of copper prices and firm cost management."

It announced a net income of US$9.8 million for its second quarter compared to a loss of $3.8 million a year earlier.

Amerigo's Q2-2024 financial results included an earnings per share (EPS) of US$0.06 compared to a loss of $0.02 a year earlier; EBITDA of US$22.3 million versus just $1.7 million; and free cash flow to equity of US$6.7 million versus a negative $12.8 million.

It returned US$3.6 million to shareholders.

Subsequent to quarter-end, on July 8, 2024, Amerigo declared its first performance dividend of C$0.04.

Aurora Davidson, Amerigo's President and CEO, in a statement said. "With our annual maintenance shutdown now completed and the impact of the previously reported rain-induced production loss absorbed, our 2024 production guidance is intact."

Davidson added: "Amerigo's Capital Return Strategy has been fully deployed with regular quarterly dividends, share buybacks, and performance dividends. At current copper prices, equivalent to those we received last quarter, we continue to generate significant amounts of capital to return to shareholders."

"The strength of Amerigo's business plan is now on full display. Shareholders have received the declaration of our initial performance dividend very well and are benefitting from the prompt transfer of copper price strength to their pockets. Our initial performance dividend will be paid in addition to our twelfth quarterly dividend of C$0.03, announced today. Despite the present short-term price correction, we anticipate continued strength in copper prices and look forward to returning capital as quickly as possible to shareholders."

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Tower Semiconductor's Q1 Adjusted Earnings, Revenue Fall; Q2 Sales Outlook Issued
Tower Semiconductor's Q1 Adjusted Earnings, Revenue Fall; Q2 Sales Outlook Issued
May 9, 2024
08:24 AM EDT, 05/09/2024 (MT Newswires) -- Tower Semiconductor ( TSEM ) reported Q1 adjusted earnings Thursday of $0.46 per diluted share, down from $0.61 a year earlier. Four analysts polled by Capital IQ expected $0.39. Revenue for the quarter ended March 31 was $327.2 million, compared with $355.6 million a year earlier. Four analysts surveyed by Capital IQ expected...
Novo Nordisk ties up with Metaphore to develop new obesity drugs
Novo Nordisk ties up with Metaphore to develop new obesity drugs
May 9, 2024
May 9 (Reuters) - Novo Nordisk signed a research tie-up with U.S. biotech firm Metaphore on Thursday to develop next-generation obesity drugs. WHY IT'S IMPORTANT Danish drugmaker Novo is trying to expand beyond its blockbuster obesity drug Wegovy with at least eight other treatments in its R&D pipeline for the condition. The collaboration will use Metaphore's tech platform to develop...
Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise
Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise
May 9, 2024
08:26 AM EDT, 05/09/2024 (MT Newswires) -- Amicus Therapeutics ( FOLD ) reported a Q1 non-GAAP net loss Thursday of $0.02 per diluted share, compared with a loss of $0.06 a year earlier. Analysts surveyed by Capital IQ expected a loss of $0.03. Net product sales for the quarter ended March 31 were $110.4 million, compared with $86.3 million a...
Viagra maker Viatris misses revenue estimates on weak demand for older drugs
Viagra maker Viatris misses revenue estimates on weak demand for older drugs
May 9, 2024
May 9 (Reuters) - Drugmaker Viatris narrowly missed first-quarter revenue estimates on Thursday, hurt by weak sales for its older drugs such as cholesterol medication Lipitor and Norvasc for high blood pressure. Net sales in its branded drugs unit, which makes up two-thirds of the company's total revenues, also fell 4.5% to $2.31 billion. Viatris ( VTRS ), formed by...
Copyright 2023-2026 - www.financetom.com All Rights Reserved